AVR remains the only effective treatment to reduce mortality in symptomatic patients with severe AS. Until recently, SAVR was considered the gold standard for most patients, with TAVI reserved primarily for those at increased surgical risk. Nonetheless, it is now evident that TAVI is non-inferior to SAVR, even in intermediate- and low-risk patients with a life expectancy of at least 8 years. TAVI is associated with lower mortality rates, fewer strokes, reduced major bleeding, decreased incidence of atrial fibrillation, and shorter hospital stays and recovery times. When the appropriate device is selected for the right patient by an experienced interventionist, the intermediate outcomes of TAVI appear comparable to those of SAVR, despite higher rates of regurgitation and conduction disturbances in TAVI patients.